基于VOSviewer对成纤维细胞生长因子23相关研究的可视化分析

Abstract
Figure/Table
References (28)
Related Citation (15)

Download: PDF (1191 KB) HTML (1 KB)
Export: BibTeX | EndNote (RIS)

Abstract Objective To analyze the research hotspot and trends of fibroblast growth factor 23 (FGF23) by visual analysis, and to provide research ideas and directions for domestic researchers. Methods Research literatures related to FGF23 were retrieved from the core collection database of Web of Science from January 2000 to May 2020, and VOSviewer software was used to conduct visual analysis of annual publication trends, countries, institutions, authors and keywords. Results A total of 3430 literatures were included, and the volume of publication showed an increasing trend year by year. The largest literature output country was United States, the most prolific author was Wolf M, and Harvard University was the research institution with the largest publication volume. The high-frequency keywords in FGF23 field included chronic kidney disease, phosphate, parathyroid hormone, vitamin D, Klotho, etc., forming five clusters. Myocardial fibrosis, uremia cardiomyopathy and its clinical treatment were the future research directions. Conclusion At present, researches related to FGF23 focus on the pathological mechanism and clinical observation studies, and there is a lack of effective targeted drug therapy studies. In the future, targeted drug research and development can be further strengthened.

Key words： Fibroblast growth factor 23 VOSviewer Visual analysis Research hotspot

	Service

	E-mail this article
	Add to my bookshelf
	Add to citation manager
	E-mail Alert
	RSS
	Articles by authors
	LIN Lamei1 DENG Danfang1 SUN Long1 WANG Xiaoqin2
	3
	4

Cite this article:

LIN Lamei1 DENG Danfang1 SUN Long1 WANG Xiaoqin2,3,4. Visual analysis of fibroblast growth factor 23 related studies based on VosViewer[J]. 中国医药导报, 2021, 18(7): 9-12,26.

URL:

http://www.yiyaodaobao.com.cn/EN/ OR http://www.yiyaodaobao.com.cn/EN/Y2021/V18/I7/9

[1] Richter B，Faul C. FGF23 Actions on Target Tissues-With and Without Klotho [J]. Front Endocrinol（Lausanne），2018， 9：189.
[2] Itoh N，Ohta H，Nakayama Y，et al. Roles of FGF Signals in Heart Development，Health，and Disease [J]. Front Cell Dev Biol，2016，4：110.
[3] Feng S，Wang J，Zhang Y，et al. FGF23 promotes prostate cancer progression [J]. Oncotarget，2015，6（19）：17291-17301.
[4] Grabner A，Schramm K，Silswal N，et al. FGF23/FGFR4-mediated left ventricular hypertrophy is reversible [J]. Sci Rep，2017，7（1）：1993.
[5] 程虹，李颖霞，王小琴，等.慢性肾脏病3～5期患者病情程度与α-Klotho、FGF23及钙、磷相关性研究[J].中国医药导报，2020，17（22）：78-81.
[6] van Eck NJ，Waltman L. Software survey：VOSviewer，a computer program for bibliometric mapping [J]. Scientometrics，2010，84（2）：523-538.
[7] 王海焦，黄锐娜，王小俊，等.基于VOSviewer的富血小板血浆研究热点主题分析[J].中国组织工程研究，2019， 23（18）：2947-2952.
[8] 张力，赵星，叶鹰.信息可视化软件CiteSpace与VOSviewer的应用比较[J].信息资源管理学报，2011，（1）：95-98.
[9] White KE，Carn G，Lorenz-Depiereux B，et al. Autosomal-dominant hypophosphatemic rickets （ADHR） mutations stabilize FGF-23 [J]. Kidney Int，2001，60（6）：2079-2086.
[10] Marcucci G，Brandi ML. Congenital Conditions of Hypophosphatemia Expressed in Adults [J]. Calcif Tissue Int，2021，108（1）：91-103.
[11] Saraff V，Nadar R，H?觟gler W. New Developments in the Treatment of X-Linked Hypophosphataemia：Implications for Clinical Management [J]. Paediatr Drugs，2020，22（2）：113-121.
[12] ADHR Consortium. Autosomal dominant hypophospha-taemic rickets is associated with mutations in FGF23 [J]. Nat Genet，2000，26（3）：345-348.
[13] Farrow EG，Imel EA，White KE. Hyperphosphatemic Familial Tumoral Calcinosis（FGF23，GALNT3，αKlotho）[J]. Best Pract Res Clin Rheumatol，2011，25（5）：735-747.
[14] Ersoy FF. A short story of Klotho and FGF23：a deuce of dark side or the savior? [J]. Int Urol Nephrol，2014，46（3）：577-581.
[15] 王小琴，王岚.中医视角下的慢性肾脏病-矿物质骨代谢异常[J].临床肾脏病杂志，2020，20（2）：99-103， 156.
[16] 宋玉，姜晨.中药干预CKD血管钙化的研究进展[J].西部中医药，2020，33（3）：150-155.
[17] Olauson H，Vervloet MG，Cozzolino M，et al. New Insights Into the FGF23-Klotho Axis [J]. Semin Nephrol，2014， 34（6）：586-597.
[18] Vogt I，Haffner D，Leifheit-Nestler M. FGF23 and Phosphate-Cardiovascular Toxins in CKD [J]. Toxins（Basel），2019，11（11）：647.
[19] 谢小街，黄凤梅，杨尚凌，等.腹膜透析治疗在老年慢性肾脏病5期合并心力衰竭患者中的应用效果[J].中国当代医药，2019，26（36）：110-112，116.
[20] 段朝阳，林燕，高洁，等.血清FGF23、FA水平与维持性血液透析患者冠状动脉钙化的关系[J].中国医药导报，2019，16（14）：117-120.
[21] 冯微微，包蓓艳，陈其军，等.血液透析对慢性肾脏病合并颈动脉粥样硬化的疗效、肾功能及微炎症状态的影响[J].中国现代医生，2019，57（20）：11-14.
[22] Shaman AM，Kowalski SR. Hyperphosphatemia Management in Patients with Chronic Kidney Disease [J]. Saudi Pharm J，2016，24（4）：494-505.
[23] Kendrick J，Cheung AK，Kaufman JS，et al. FGF-23 associates with death，cardiovascular events，and initiation of chronic dialysis [J]. J Am Soc Nephrol，2011，22（10）：1913-1922.
[24] Bouma-de Krijger A，Vervloet MG. Fibroblast growth factor 23：are we ready to use it in clinical practice? [J]. J Nephrol，2020，33（3）：509-527.
[25] Fassett RG，Venuthurupalli SK，Gobe GC，et al. Biomarkers in chronic kidney disease：a review [J]. Kidney Int，2011，80（8）：806-821.
[26] Kramann R，Erpenbeck J，Schneider RK，et al. Speckle tracking echocardiography detects uremic cardiomyopathy early and predicts cardiovascular mortality in ESRD [J]. J Am Soc Nephrol，2014，25（10）：2351-2365.
[27] Kaesler N，Babler A，Floege J，et al. Cardiac Remodeling in Chronic Kidney Disease [J]. Toxins（Basel），2020，12（3）：161.
[28] Law JP，Price AM，Pickup L，et al. Clinical Potential of Targeting Fibroblast Growth Factor-23 and αKlotho in the Treatment of Uremic Cardiomyopathy [J]. J Am Heart Assoc，2020，9（7）：e016041.